FIELD: organic chemistry, pharmacy.
SUBSTANCE: invention relates to anthranylamidepyridine amides of selective effect as inhibitors of VEGFR-2 and VEGFR-3. Invention describes compounds of the general formula (I): 
wherein A, B and D represent independently of one another nitrogen atom or carbon atom wherein at least one nitrogen atom is in a ring; E represents aryl comprising 6-12 ring carbon atoms or heteroaryl comprising 5 or 6 ring atoms and comprising in ring instead carbon atom similar or different heteroatoms chosen from nitrogen or sulfur atoms, or represents group -COOR8, -CONR2R3 or -C≡C-R9; G represents nitrogen atom or group -C-X; L represents nitrogen atom or group -C-X; M represents nitrogen atom or group -C-X; Q represents nitrogen atom or group -C-X and wherein a ring comprises maximally one nitrogen atom; X represents hydrogen atom; W represents hydrogen or halogen atom; R1 represents aryl similarly or differently optionally mono- or multi-substituted with halogen atom, hydroxy-, (C1-C6)-alkoxy-group, (C1-C6)-alkyl or group =O and wherein aryl comprises 6-12 ring carbon atoms, or heteroaryl comprising from 3 to 16 ring atoms and comprising in ring instead carbon one or more similar or different heteroatoms, such as oxygen, nitrogen or sulfur and it can be mono-, bi- or tricyclic and condensed additionally condensed with benzene ring; R2 and R3 represent independently of one another hydrogen atom or aryl similarly or differently mono- or multi-substituted with halogen atom, cyano-group, (C1-C6)-alkyl, phenyl, hydroxy-(C1-C6)-alkyl, halogen-(C1-C6)-alkyl or group -NR6R7, -OR5, (C1-C6)-alkyl-OR5-(C1-C6)-alkyl, (C3-C6)-cycloalkyl, (C3-C6)-cycloalkenyl wherein aryl comprises 6-12 ring carbon atoms, or heteroaryl comprising from 3 to 6 ring atoms and comprising in ring instead carbon one or more heteroatoms, such as nitrogen or sulfur; or R2 and R3 in common with nitrogen atom form (C3-C8)-ring that can comprise optionally one more nitrogen or oxygen atom or it can comprise group -N(R10); R5 represents hydrogen atom; R6 and R7 represent independently of one another hydrogen atom or (C1-C6)-alkyl; R8 represents (C1-C6)-alkyl mono- or multi-substituted optionally with halogen atom or benzyl; R9 represents hydrogen atom or tri-(C1-C6)-alkylsilyl; R10 represents hydrogen atom or (C1-C6)-alkyl, and their isomers, enantiomers and salts also. Also, invention describes a medicinal agent based on compounds of the formula (I). Invention provides synthesis of novel compounds possessing valuable biological properties.
EFFECT: valuable medicinal properties of compounds.
8 cl, 2 tbl, 162 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTHRANYLAMIDES AND THEIR USING AS MEDICINAL AGENTS | 2001 |
|
RU2263664C2 |
| NEW ANTHRANILAMIDOPYRIDINEUREAS AS VEGF RECEPTOR KINASE INHIBITORS | 2005 |
|
RU2415850C2 |
| NEW DERIVATIVES OF HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD FOR MODULATION OF AUTOIMMUNE DISEASES, METHOD FOR PREPARING THESE COMPOUNDS | 2000 |
|
RU2255937C2 |
| AZAINDOL DERIVATIVES AS FACTOR Xa INHIBITORS | 2004 |
|
RU2330853C2 |
| DERIVATIVES OF BENZIMIDAZOL INHIBITING FACTOR Xa | 2004 |
|
RU2346944C2 |
| NOVEL COMPOUNDS | 2016 |
|
RU2734256C2 |
| SUBSTITUTED AMIDES OF BENZOIC ACID AND PHARMACEUTICAL PREPARATION CONTAINING THEM | 2001 |
|
RU2353618C2 |
| INDOLE-2-CARBOXAMIDES AS INHIBITORS OF FACTOR Xa AND/OR VIIa, MEDICINAL AGENT BASED ON THEREOF AND METHOD FOR THEIR PREPARING | 2002 |
|
RU2299881C2 |
| ISOSERINE DERIVATIVES APPLIED AS BLOOD COAGULATION FACTOR IXA INHIBITORS | 2007 |
|
RU2446157C2 |
| CARBOXAMIDE COMPOUNDS AND USING THEM AS CALPAIN INHIBITORS | 2010 |
|
RU2540856C2 |
